NCT00786240View on ClinicalTrials.gov

Phase1, Single Dose, Crossover Study to Determine Bioequivalence

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
Healthy
Interventions
DRUG

Fesoterodine

Single dose of 4 mg tablet in formulation D under fasted conditions (Reference)

DRUG

Fesoterodine

Single dose of 4 mg tablet in formulation E(1) under fasted conditions (Test)

Trial Locations (1)

188770

Pfizer Investigational Site, Singapore

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00786240 - Phase1, Single Dose, Crossover Study to Determine Bioequivalence | Biotech Hunter | Biotech Hunter